Clinical trial
A Phase 1 Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GS1-144 Tablets
NCT06204250 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GS1-144 Tablets
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 27, 2024
- Completion date
- December 19, 2024
- Enrollment
- 86 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult healthy volunteers, vasomotor symptoms